Skip to main content
Smart Investors Daily
AS

NASDAQ · ASBPW

Aspire Biopharma Holdings, Inc.

Healthcare · Biotechnology

$0.01

Up+$0.00 (+0.00%)

Updated Aug 25, 2026, 5:59 PM

SID Score

2.9/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
6.21M
P/E ratio
-9.59
Dividend yield
0.00%
52-week range
$0.01 – $0.03
Volume
3.28K
Avg. volume
36.09K

Price performance

ASBPW price history

1M range · 14 trading sessions · Daily adjusted prices

ASBPW closed at $0.01 after 14 trading sessions, down 45.83% for the selected period.

Last close
$0.01
Period change
-45.83%
Period low
$0.01
Period high
$0.02
Daily close
View OHLC price history
ASBPW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 24, 2026$0.013$0.013$0.013$0.0133.28K
Aug 21, 2026$0.0153$0.0153$0.013$0.01313.75K
Aug 20, 2026$0.0183$0.0183$0.0116$0.0158246.47K
Aug 19, 2026$0.0236$0.0236$0.021$0.0211.75K
Aug 18, 2026$0.0237$0.0237$0.0183$0.018326.75K
Aug 17, 2026$0.02$0.0237$0.0195$0.01953.88K
Aug 14, 2026$0.0183$0.0183$0.0183$0.0183207
Aug 13, 2026$0.0191$0.02$0.0183$0.018312.71K
Aug 12, 2026$0.022$0.022$0.02$0.0205297.13K
Aug 11, 2026$0.02$0.02$0.02$0.027.9K
Aug 5, 2026$0.024$0.024$0.0186$0.0186800
Jul 29, 2026$0.0185$0.0185$0.0185$0.0185325
Jul 28, 2026$0.0238$0.024$0.0238$0.0249K
Jul 27, 2026$0.0181$0.024$0.0181$0.024757

Latest ASBPW news

The latest Smart Investors Daily articles mentioning ASBPW.

ASBPW research

Overview

Company profile and research snapshot.

Company profile

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jun 17, 2026

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.’s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026. DATE: June 25th TIME: 2:00 pm ET REGISTER HERE Available for 1x1 meetings: June 24-25. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within th

Yahoo · Jun 12, 2026

Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)

Aspire Biopharma has agreed to acquire Dura Driver Control Systems, a global automotive supplier with more than $200 million in annual revenue, significantly reshaping the company’s revenue base and business mix. Key Investor TakeawaysAspire Biopharma (NASDAQ:ASBP) has signed a definitive agreement to acquire Dura Driver Control Systems for $30 million in cash.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.